Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis

Borja de la Sen-Corcuera,1,2 Jesús Montero-Iruzubieta,3,4 Ronald M Sánchez-Ávila,1,5 Gorka Orive,1,2 Eduardo Anitua,1,2 Manuel Caro-Magdaleno,4 Jesús Merayo-Lloves5 1Biotechnology Institute (BTI), Vitoria, Spain; 2University Institute for Regenerative Medi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	de la Sen-Corcuera B, Montero-Iruzubieta J, Sánchez-Ávila RM, Orive G, Anitua E, Caro-Magdaleno M, Merayo-Lloves J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	immunosafe plasma rich in growth factors (isprgf) stevens-johnson syndrome ocular mucous membrane pemphigoid blood derivatives Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f0cb3e1acbf148d8b22b16d9a9564bde
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0cb3e1acbf148d8b22b16d9a9564bde
record_format	dspace
spelling	oai:doaj.org-article:f0cb3e1acbf148d8b22b16d9a9564bde2021-12-02T08:13:03ZPlasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis1177-5483https://doaj.org/article/f0cb3e1acbf148d8b22b16d9a9564bde2020-06-01T00:00:00Zhttps://www.dovepress.com/plasma-rich-in-growth-factors-for-the-treatment-of-cicatrizing-conjunc-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Borja de la Sen-Corcuera,1,2 Jesús Montero-Iruzubieta,3,4 Ronald M Sánchez-Ávila,1,5 Gorka Orive,1,2 Eduardo Anitua,1,2 Manuel Caro-Magdaleno,4 Jesús Merayo-Lloves5 1Biotechnology Institute (BTI), Vitoria, Spain; 2University Institute for Regenerative Medicine and Oral Implantology (UIRMI), Vitoria, Spain; 3Clínica Cartujavisión, Sevilla, Spain; 4Hospital Universitario Virgen de Macarena, Sevilla, Spain; 5Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Oviedo, SpainCorrespondence: Ronald M Sánchez-ÁvilaInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Avda Dres Fernández-Vega Num 34, Oviedo E-33012 Principado de Asturias, SpainTel +34 985240141Fax +34 985233288Email ronald.sanchezavila@gmail.comPurpose: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy.Patients and Methods: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated.Results: Ten eyes (6 patients) were evaluated, 50% corresponded to Stevens–Johnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 ± 16.5 (39– 80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 ± 6.7 (13.6– 30.3) months. No adverse effects were reported.Conclusion: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.Keywords: immunosafe plasma rich in growth factors, isPRGF, Stevens–Johnson syndrome, ocular mucous membrane pemphigoid, blood derivativesde la Sen-Corcuera BMontero-Iruzubieta JSánchez-Ávila RMOrive GAnitua ECaro-Magdaleno MMerayo-Lloves JDove Medical Pressarticleimmunosafe plasma rich in growth factors (isprgf)stevens-johnson syndromeocular mucous membrane pemphigoidblood derivativesOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 1619-1627 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunosafe plasma rich in growth factors (isprgf) stevens-johnson syndrome ocular mucous membrane pemphigoid blood derivatives Ophthalmology RE1-994
spellingShingle	immunosafe plasma rich in growth factors (isprgf) stevens-johnson syndrome ocular mucous membrane pemphigoid blood derivatives Ophthalmology RE1-994 de la Sen-Corcuera B Montero-Iruzubieta J Sánchez-Ávila RM Orive G Anitua E Caro-Magdaleno M Merayo-Lloves J Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
description	Borja de la Sen-Corcuera,1,2 Jesús Montero-Iruzubieta,3,4 Ronald M Sánchez-Ávila,1,5 Gorka Orive,1,2 Eduardo Anitua,1,2 Manuel Caro-Magdaleno,4 Jesús Merayo-Lloves5 1Biotechnology Institute (BTI), Vitoria, Spain; 2University Institute for Regenerative Medicine and Oral Implantology (UIRMI), Vitoria, Spain; 3Clínica Cartujavisión, Sevilla, Spain; 4Hospital Universitario Virgen de Macarena, Sevilla, Spain; 5Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Oviedo, SpainCorrespondence: Ronald M Sánchez-ÁvilaInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Avda Dres Fernández-Vega Num 34, Oviedo E-33012 Principado de Asturias, SpainTel +34 985240141Fax +34 985233288Email ronald.sanchezavila@gmail.comPurpose: The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy.Patients and Methods: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated.Results: Ten eyes (6 patients) were evaluated, 50% corresponded to Stevens–Johnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 ± 16.5 (39– 80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 ± 6.7 (13.6– 30.3) months. No adverse effects were reported.Conclusion: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.Keywords: immunosafe plasma rich in growth factors, isPRGF, Stevens–Johnson syndrome, ocular mucous membrane pemphigoid, blood derivatives
format	article
author	de la Sen-Corcuera B Montero-Iruzubieta J Sánchez-Ávila RM Orive G Anitua E Caro-Magdaleno M Merayo-Lloves J
author_facet	de la Sen-Corcuera B Montero-Iruzubieta J Sánchez-Ávila RM Orive G Anitua E Caro-Magdaleno M Merayo-Lloves J
author_sort	de la Sen-Corcuera B
title	Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_short	Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_full	Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_fullStr	Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_full_unstemmed	Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis
title_sort	plasma rich in growth factors for the treatment of cicatrizing conjunctivitis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f0cb3e1acbf148d8b22b16d9a9564bde
work_keys_str_mv	AT delasencorcuerab plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis AT monteroiruzubietaj plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis AT sanchezavilarm plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis AT oriveg plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis AT anituae plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis AT caromagdalenom plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis AT merayollovesj plasmarichingrowthfactorsforthetreatmentofcicatrizingconjunctivitis
_version_	1718398638381596672

Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis

Ejemplares similares